A new trading day began on Friday, with Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock price down -4.69% from the previous day of trading, before settling in for the closing price of $12.80. ARCT’s price has ranged from $8.04 to $45.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 301.31%. Meanwhile, its annual earnings per share averaged -13.41%. With a float of $24.83 million, this company’s outstanding shares have now reached $27.12 million.
Let’s determine the extent of company efficiency that accounts for 176 employees. In terms of profitability, gross margin is 100.84%, operating margin of -47.08%, and the pretax margin is -50.73%.
Arcturus Therapeutics Holdings Inc (ARCT) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcturus Therapeutics Holdings Inc is 8.44%, while institutional ownership is 91.67%. The most recent insider transaction that took place on Oct 15 ’24, was worth 249,121. In this transaction Chief Scientific Officer & COO of this company sold 12,000 shares at a rate of $20.76, taking the stock ownership to the 435,334 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 12,000 for $20.76, making the entire transaction worth $249,121.
Arcturus Therapeutics Holdings Inc (ARCT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -13.41% per share during the next fiscal year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Here are Arcturus Therapeutics Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.52, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -2.76 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Looking closely at Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), its last 5-days average volume was 0.38 million, which is a drop from its year-to-date volume of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 53.37%. Additionally, its Average True Range was 1.00.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 31.47%, which indicates a significant decrease from 47.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.90% in the past 14 days, which was higher than the 76.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.62, while its 200-day Moving Average is $16.82. However, in the short run, Arcturus Therapeutics Holdings Inc’s stock first resistance to watch stands at $12.70. Second resistance stands at $13.21. The third major resistance level sits at $13.61. If the price goes on to break the first support level at $11.79, it is likely to go to the next support level at $11.39. Now, if the price goes above the second support level, the third support stands at $10.88.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
With a market capitalization of 330.87 million, the company has a total of 27,121K Shares Outstanding. Currently, annual sales are 152,310 K while annual income is -80,940 K. The company’s previous quarter sales were 29,380 K while its latest quarter income was -14,080 K.
